1. |
Mercatali L, Ibrahim T, Sacanna E, et al. Bone metastases detection by circulating biomarkers: OPG and rank-L[J]. Int J Oncol, 2011, 39(1): 255-261.
|
2. |
Boyle WJ, Scott SW, Lacey DL. Osteoclast differentiation and activation[J]. Nature, 2003, 423(6937): 337-342.
|
3. |
Boyce BF, Hughes DE, Wright KR, et al. Recent advances in bone biologyprovide insight into the pathogenesis of bone diseases[J]. Lab Invest, 1999, 79(2): 83-94.
|
4. |
Tometsko M, Roudier M, Canon J, et al. Rank-L inhibition causes a greater suppressionof tumor-induced osteoclastogenesis than zoledronate treatment in vivo and rank-L rescues osteoclasts from zoledronate killing in vitro[J]. Am Soc Bone Miner Res, 2006, 21(Suppl 1): Abstract M076.
|
5. |
Boyce BF, Xing L. Biology of RANK, RANK-L, and osteoprotegerin[J]. Arthritis Res Ther, 2007, 1(Suppl 9): S1.
|
6. |
田明嫄, 黄安斌. Denosumab在骨破坏性疾病中的应用进展[J]. 中华风湿病学杂志, 2009, 13(5): 349-352.
|
7. |
Santini D, Galluzzo S, Zoccoli A, et al. New molecular targets in bone metastases[J]. Cancer Treat Rev, 2010, 36(Suppl 3): S6-S10.
|
8. |
Reddy GK, Nadler E, Jain VK. Denosumab (AMG 162), a fully human monoclonal antibody against rank ligand activity[J]. Support Cancer Ther, 2005, 3(1): 14-15.
|
9. |
Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer[J]. J Clin Oncol, 2008, 26(30): 4875-4882.
|
10. |
Paget S. The distribution of secondary growths in cancer of the breast[J]. Lancet, 1889, 133(3421): 571-573.
|
11. |
Holstead JD, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by rankl[J]. Nature, 2006, 440(7084): 692-696.
|
12. |
Vignot S, Khayat D. A step in the journey of denosumab from bone-targeted therapy to seed-and soil-targeted therapy[J]. J Clin Oncol, 2009, 27(10): 1534-1536.
|
13. |
Roodman GD. Mechanisms of bone metastasis[J]. N Engl J Med, 2004, 350(16): 1655-1664.
|
14. |
Terpos E, Efstathiou E, Christoulas D, et al. Rankl inhibition:clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases[J]. Expert Opin Biol Ther, 2009, 9(4): 465-479.
|
15. |
Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappab ligand inhibitor,denosumab,in patients with multiple myeloma or bone metastases from breast cancer[J]. Clin Cancer Res, 2006, 12(4): 1221-1228.
|
16. |
Yonemori K, Fujiwara Y, Minami H, et al. Phase 1 trial of denosumab safety,pharmacokinetics,and pharmacodynamics in japanese women with breast cancer-related bone metastases[J]. Cancer Sci, 2008, 99(6): 1237-1242.
|
17. |
Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases[J]. J Clin Oncol, 2007, 25(28): 4431-4437.
|
18. |
Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized,double-blind study[J]. J Clin Oncol, 2010, 28(35): 5132-5139.
|
19. |
Castellano D, Sepulveda JM, García-escobar I, et al. The role of rank-ligand inhibition in cancer:the story of denosumab[J]. Oncologist, 2011, 16(2): 136-145.
|
20. |
Scott LJ, Muir VJ. Denosumab:in the prevention of skeletal-related events in patients with bone metastases from solid tumours[J]. Drugs, 2011, 71(8): 1059-1069.
|
21. |
Barton MK. Denosumab an option for patients with bone metastasis from breast cancer[J]. CA Cancer J Clin, 2011, 61(3): 135-136.
|